Search results

A leading developer of novel cancer therapeutics was experiencing persistent manufacturing process issues. Our engineers were able to diagnose and solve two problems.

Learn 5 practical strategies to reduce AI hallucination in clinical research to improve accuracy, transparency, compliance, and decision-making.

The 2025 Year in Review highlights 30 years of drug development expertise, key milestones, events, resources, and innovations shaping early-phase research.

See how Altasciences supported a sponsor’s 505(b)(2) submission with three pivotal studies, driving simulation, bioavailability, and dose-escalation, to deliver critical data.

Gretchen Green recaps the ARVO 2025 annual meeting, highlighting AI in ophthalmology, gene therapy, and preclinical advances in ocular safety and drug delivery.

Early-phase drug development is a complex process. Discover how Altasciences, as an integrated CRO/CDMO, alleviates the challenges and reduces risks.